1. Andrews WC. The transitional years and beyond. Obstet Gynecol 1995; 851):1-5.

2. Ravnikar VA. Compliance with hormone replacement therapy: are women receiving the full impact of hormone replacement therapy preventive health benefits? Womens Health Issues 1992; 22):75-80.

3. Longcope C, Jaffee W, Griffing G. Metabolic clearance rates of androgens and oestrogens in ageing women. Maturitas 1980; 24):283-290.

4. Slemenda CW, Hui SL, Longcope C, Wellman H, Johnston CC, Jr. Predictors of bone mass in perimenopausal women. A prospective study of clinical data using photon absorptiometry. Ann Intern Med 1990; 1122):96-101.

5. Kronenberg F. Hot flashes. In: Lobo RA, editor. Treatment of the postmenopausal woman. Philadelphia, PA: Lippincott-Raven Publishers, 1996: 97-117.

6. Aksel S, Schomberg DW, Tyrey L, Hammond CB. Vasomotor symptoms, serum estrogens, and gonadotropin levels in surgical menopause. Am J Obstet Gynecol 1976; 1262):165-169.

7. Schiff I, Regestein Q, Tulchinsky D, Ryan KJ. Effects of estrogens on sleep and psychological state of hypogonadal women. JAMA 1979; 24222):2405-4.

8. Oriba HA, Maibach HI. Vulvar transepidermal water loss TEWL) decay curves. Effect of occlusion, delipidation, and age. Acta Derm Venereol 1989; 696):461-465.

9. Sherwin BB, Gelfand MM. The role of androgen in the maintenance of sexual functioning in oophorectomized women. Psychosom Med 1987; 494):397-409.

10. Davies KM, Pearson PH, Huseman CA, Greger NG, Kimmel DK, Recker RR. Reduced bone mineral in patients with eating disorders. Bone 1990; 11:143-147.

11. Riggs BL, Wahner HW, Melton LJ, III, Richelson LS, Judd HL, Offord KP. Rates of bone loss in the appendicular and axial skeletons of women. Evidence of substantial vertebral bone loss before menopause. J Clin Invest 1986; 77 5):1487-1491.

12. Kiel DP, Felson DT, Anderson JJ, Wilson PW, Moskowitz MA. Hip fracture and the use of estrogens in postmenopausal women. The Framingham Study. N Engl J Med 1987; 317 19):1169-1174.

13. Quigley ME, Martin PL, Burnier AM, Brooks P. Estrogen therapy arrests bone loss in elderly women. Am J Obstet Gynecol 1987; 1566):1516-1523.

14. Corson SL. A practical guide to prescribing estrogen replacement therapy. Int J Fertil Menopausal Stud 1995; 405):229-247.

15. Anderson RN. Deaths: leading causes for 1999. Natl Vital Stat Rep 2001; 4911):1-87.

16. Matthews KA, Meilahn E, Kuller LH, Kelsey SF, Caggiula AW, Wing RR. Menopause and risk factors for coronary heart disease. N Engl J Med 1989; 321 10):641-646.

17. Alexander KP, Newby LK, Hellkamp AS, Harrington RA, Peterson ED, Kopecky S et al. Initiation of hormone replacement therapy after acute myocardial infarction is associated with more cardiac events during follow-up. J Am Coll Cardiol 2001; 381):1-7.

18. Heckbert SR, Kaplan RC, Weiss NS, Psaty BM, Lin D, Furberg CD et al. Risk of recurrent coronary events in relation to use and recent initiation of postmenopausal hormone therapy. Arch Intern Med 2001; 16114):1709-1713.

19. Grodstein F, Manson JE, Stampfer MJ. Postmenopausal hormone use and secondary prevention of coronary events in the nurses' health study. a prospective, observational study. Ann Intern Med 2001; 1351):1-8.

20. Hodis HN, Mack WJ, Lobo RA, Shoupe D, Sevanian A, Mahrer PR et al. Estrogen in the prevention of atherosclerosis. A randomized, double- blind, placebo-controlled trial. Ann Intern Med 2001; 13511):939-953.

21. Hulley S, Grady D, Bush T, Furberg C, herrington D, Riggs B et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998; 280:605-613.

22. Herrington DM, Reboussin DM, Brosnihan BK, et al. Effects of estrogen replacement on the progression of coronary artery athersclerosis. N Eng J Med 0 AD/8/24; 3438):522-529.

23. Fahraeus L. The effects of estradiol on blood lipids and lipoproteins in postmenopausal women. Obstet Gynecol 1988; 725 Suppl):18S-22S.

24. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: the postmenopausal estrogen/progestin interventions PEPI) trial. JAMA 1995; 273:199-208.

25. Sarrel PM, Lindsay D, Rosano GMC, Poole-Wilson PA. Angina and normal coronary arteries in women: Gynecologic findings. Am J Obstet Gynecol 1992; 167:467-472.

26. Rosano GM, Sarrel PM, Poole-Wilson PA, Collins P. Beneficial effect of oestrogen on exercise-induced myocardial ischaemia in women with coronary artery disease. Lancet 1993; 3428864):133-136.

27. Gangar KF, Vyas S, Whitehead M, Crook D , Meire H, Campbell S. Pulsatility index in internal carotid artery in relation to transdermal oestradiol and time since menopause. Lancet 1991; 3388771):839-842.

28. Viscoli CM, Brass LM, Kernan WN, Sarrel PM, Suissa S, Horwitz RI. A clinical trial of estrogen-replacement therapy after ischemic stroke. N Engl J Med 2001; 34517):1243-1249.

29. Feuer EJ, Wun LM, Boring CC, Flanders WD, Timmel MJ, Tong T. The lifetime risk of developing breast cancer. J Natl Cancer Inst 1993; 8511):892-897.

30. Cancer Facts & Figures, 2001. 2001. Atlanta, Ga., American Cancer Society.
Ref Type: Report

31. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet 1997; 3509084):1047-1059.

32. Dupont WD, Page DL. Menopausal estrogen replacement therapy and breast cancer. Arch Intern Med 1991; 1511):67-72.

33. Sellers TA, Mink PJ, Cerhan JR, Zheng W , Anderson KE, Kushi LH et al. The role of hormone replacement therapy in the risk for breast cancer and total mortality in women with a family history of breast cancer . Ann Intern Med 1997; 12711):973-980.

34. Gapstur SM, Morrow M, Sellers TA. Hormone replacement therapy and risk of breast cancer with a favorable histology: results of the Iowa Women's Health Study. JAMA 1999; 28122):2091-2097.

35. Colditz GA, Egan KM, Stampfer MJ. Hormone replacement therapy and risk of breast cancer: results from epidemiologic studies. Am J Obstet Gynecol 1993; 1685):1473-1480.

36. Bergkvist L, Adami HO, Persson I, Bergstrom R, Krusemo UB. Prognosis after breast cancer diagnosis in women exposed to estrogen and estrogen-progestogen replacement therapy. Am J Epidemiol 1989; 1302):221-228.

37. Strickland DM, Gambrell RD, Jr., Butzin CA, Strickland K. The relationship between breast cancer survival and prior postmenopausal estrogen use. Obstet Gynecol 1992; 803 Pt 1):400-404.

38. Bonnier P, Romain S, Giacalone PL, Laffargue F, Martin PM, Piana L. Clinical and biologic prognostic factors in breast cancer diagnosed during postmenopausal hormone replacement therapy. Obstet Gynecol 1995; 851):11-17.

39. Boyd NF, Lockwood GA, Byng JW, Tritchler DL, Yaffe MJ. Mammographic densities and breast cancer risk. Cancer Epidemiol Biomarkers Prev 1998; 712):1133-1144.

40. Greendale GA, Reboussin BA, Sie A, Singh HR, Olson LK, Gatewood O et al. Effects of estrogen and estrogen-progestin on mammographic parenchymal density. Postmenopausal Estrogen/Progestin Interventions PEPI) Investigators. Ann Intern Med 1999; 1304 Pt 1):262-269.

41. Rutter CM, Mandelson MT, Laya MB, Seger DJ, Taplin S. Changes in breast density associated with initiation, discontinuation, and continuing use of hormone replacement therapy. JAMA 2001; 2852):171-176.

42. Ross RK, Paganini-Hill A, Wan PC, Pike MC. Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst 2000; 924):328-332.

43. Gambrell RD, Jr. The menopause: benefits and risks of estrogen-progestogen replacement therapy. Fertil Steril 1982; 374):457-474.

44. Persson I, Yuen J, Bergkvist L, Schairer C. Cancer incidence and mortality in women receiving estrogen and estrogen- progestin replacement therapy--long-term follow-up of a Swedish cohort. Int J Cancer 1996; 673):327-332.

45. Pickar JH, Yeh I, Wheeler JE, Cunnane MF, Speroff L. Endometrial effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate. Fertil Steril 2001; 761):25-31.

46. Pfaff DW. Estrogens and Brain Function. New York, NY: Springer-Verlag, 1980.

47. Bartus RT, Dean RL, III, Beer B, Lippa AS. The cholinergic hypothesis of geriatric memory dysfunction. Science 1982; 2174558):408-414.

48. Ditkoff EC, Crary WG, Cristo M, Lobo RA . Estrogen improves psychological function in asymptomatic postmenopausal women. Obstet Gynecol 1991; 786):991-995.

49. Kampen DL, Sherwin BB. Estrogen use and verbal memory in healthy postmenopausal women. Obstet Gynecol 1994; 836):979-983.

50. Sherwin BB. Estrogen effects on cognition in menopausal women. Neurology 1997; 485 Suppl 7):S21-S26.

51. Resnick SM, Metter EJ, Zonderman AB. Estrogen replacement therapy and longitudinal decline in visual memory. A possible protective effect? Neurology 1997; 496):1491-1497.

52. Evans DA, Funkenstein HH, Albert MS, Scherr PA, Cook NR, Chown MJ et al. Prevalence of Alzheimer's disease in a community population of older persons. Higher than previously reported. JAMA 1989; 26218):2551-2556.

53. Berlinger WG, Potter JF. Low Body Mass Index in demented outpatients. J Am Geriatr Soc 1991; 39 10):973-978.

54. Mulnard RA, Cotman CW, Kawas C, van Dyck CH, Sano M, Doody R et al. Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. Alzheimer's Disease Cooperative Study. JAMA 2000; 2838):1007-1015.

55. Grodstein F, Stampfer MJ, Goldhaber SZ, et al. Prospective study of exogenous hormones and risk of pulmonary embolism in women. Lancet 1996; 348:983-987.

56. Grodstein F, Colditz GA, Stampfer MJ. Postmenopausal hormone use and cholecystectomy in a large prospective study. Obstet Gynecol 1994; 831):5-11.

57. Vingerling JR, Dielemans I, Witteman JC, Hofman A, Grobbee DE, de Jong PT. Macular degeneration and early menopause: a case-control study. BMJ 1995; 3106994):1570-1571.

58. Risk factors for neovascular age-related macular degeneration. The Eye Disease Case-Control Study Group. Arch Ophthalmol 1992; 11012):1701-1708.

59. Klein BE, Klein R, Jensen SC, Ritter LL . Are sex hormones associated with age-related maculopathy in women? The Beaver Dam Eye Study. Trans Am Ophthalmol Soc 1994; 92:289-295.

60. Bolognia JL. Aging skin. Am J Med 1995; 981A):99S-103S.

61. Pierard GE, Letawe C, Dowlati A, Pierard-Franchimont C. Effect of hormone replacement therapy for menopause on the mechanical properties of skin. J Am Geriatr Soc 1995; 436):662-665.

62. Ashcroft GS, Dodsworth J, van Boxtel E, Tarnuzzer RW, Horan MA, Schultz GS et al. Estrogen accelerates cutaneous wound healing associated with an increase in TGF-beta1 levels. Nat Med 1997; 311):1209-1215.

63. Jeffcoat MK, Chesnut CH, III. Systemic osteoporosis and oral bone loss: evidence shows increased risk factors. J Am Dent Assoc 1993; 12411):49-56.

64. Grodstein F, Colditz GA, Stampfer MJ. Post-menopausal hormone use and tooth loss: a prospective study. J Am Dent Assoc 1996; 1273):370-7, quiz.

65. Campbell S. The Management of the Menopause and the Post-Menopausal Years. Baltimore, Md.: University Park Press, 1976.

66. Writing Group for the Women's Health Initiative Investigators. Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled Trial. JAMA 2002; 288(3):321-333.

67. Breast Cancer and Hormone Replacement Therapy in the Million Women Study. Lancet 2003; 362: 419-47.

68. Utian WH, Shoupe D, Bachmann G, et al. Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate. Fertil Sterl. 2001; 75(6): 1065-1079.

69. Hlatky MA, Boothroyd D, Vittinghoff E, et al for the HERS Research Group. Quality of life and depressive symptoms in postmenopausal women after receiving hormone therapy. Results from the Heart and Estrogen/Progestin Replacement Study (HERS) Trial. JAMA 2002;287:591-597.

70. Soares CDN, Almeida OP, Joffe H, Cohen LS. Efficacy of estradiol for the treatment of depressive disorders in perimenopausal women. A double-blind, randomized, placebo-controlled trial. Arch Gen Psychiatry 2001;58: 529-534.

71. Sherwin BB, Gelfand MM. Sex steroids and affect in the surgical menopause: a double-blind, cross-over study. Psychoneuroendocrinology 1985;10: 325-335.

72. Sherwin BB. Affective changes with estrogen and androgen replacement therapy in surgically menopausal women. J Affect Disord 1988;14: 177-187.

73. Lindsay R, Gallagher JC, Kleerekoper M, Pickar JH. Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women. JAMA 2002;287: 2668-2676.

74. Delmas PD, Hardy P, Garnero P, Dain M-P. Monitoring individual response to hormone replacement therapy with bone markers. Bone 2000;26: 553-560.

75. Hunt K, Vessey M, McPherson K. Mortality in a cohort of long-term users of hormone replacement therapy: an updated analysis. Br J Obstet Gynaecol 1990;97: 1080-1086.

76. Henderson BE, Paganini-Hill A, Ross RK. Decreased mortality in users of estrogen replacement therapy. Arch Intern Med 1991;151: 75-78.

77. Willis DB, Calle EE, Miracle-McMahill HL, Heath CW Jr. Estrogen replacement therapy and risk of fatal breast cancer in a prospective cohort of postmenopausal women in the United States. Cancer Causes Control 1996;7: 449-457.

78. Grodstein F, Stampfer MJ, Colditz GA, et al. Postmenopausal hormone therapy and mortality. N Engl J Med 1997;336: 1769-1775.

79. Sellers TA, Mink PJ, Cerhan JR, et al. The role of hormone replacement therapy in the risk for breast cancer and total mortality in women with a family history of breast cancer. Ann Intern Med 1997;127:973-980.

80. Rodriguez C, Calle EE, Patel AV, Tatham LM, Jacobs EJ, Thun MJ. Effect of body mass on the association between estrogen replacement therapy and mortality among elderly US women. Am J Epidemiol 2001;153: 145-152.

81. Holli K, Isola J, Cuzick J. Low biologic aggressiveness in breast cancer in women using hormone replacement therapy. J Clin Oncol 1998;16: 3115-3120.

82. Sellers TA, Mink PJ, Cerhan JR, et al. The role of hormone replacement therapy in the risk for breast cancer and total mortality in women with a family history of breast cancer. Ann Intern Med 1997;127: 973-980.

83. Rebbeck TA, Levin AM, Eisen A, et al. Breast Cancer risk after bilateral prophylactic oophorectomy in BCRA1 mutation carriers. J Natl Cancer Inst 1999;91: 1475-1479.

84. O’Mears ES, Rossing MA, Daling JR, et al. Hormone replacement therapy after a diagnosis of breast cancer in relation to recurrence and mortality. J Natl Cancer Inst 2001;93: 745-761.

85. Durna EM, Wren BG, Heller GZ, et al. Hormone replacement therapy after a diagnosis of breast cancer: cancer recurrence and mortality. Med J Aust 2002;177: 347-351.

86. Anderson GL, Judd HL, Kaunitz AM,et al. Women's Health Initiative Investigator Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women's Health Initiative randomized trial. JAMA 2003 Oct 1;290(13): 1739-1748.

87. Hulley S, Furberg C, Barrett-Connor E, et al. Noncardiovascular disease outcomes during 6.8 years of hormone therapy: heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 2002;288: 58-66.

88. Coughlin SS, Glustozzi A, Smith SJ, Lee NC. A meta-analysis of estrogen replacement therapy and risk of epithelial ovarian cancer. J Clin Epidemiol 2000;53: 367-375.

89. Behl C, Skutella T, Lezoualc’h F, et al. Neuroprotection against oxidative stress by estrogens: structure-activity relationship. Mol Pharmacol. 1997;51: 535-541.

90. Singer CA, Figueroa-Masot XA, Batchelor RH, Dorsa DM. The mitogen-activated protein kinase pathway mediates estrogen neuroprotection after glutamate toxicity in primary cortical neurons. J Neurosci 1999;19: 2455-2463.

91. Dubal DB, Wilson ME, Wise PM. Estradiol: a protective and trophic factor in the brain. Alzheimer Dis Rev 1999;4: 1-9.

92. Kawas C, Resnick S, Morrison A, et al. A prospective study of estrogen replacement therapy and the risk of developing Alzheimer’s disease: the Baltimore Longitudinal Study of Aging. Neurology 1997;48: 1517-1521.

93. Paganini-Hill A, Henderson VW. Estrogen replacement therapy and risk of Alzheimer disease. Arch Intern Med 1996;156: 2213-2217.

94. Zandi PP, Carlson MC, Plassman BL, et al. Hormone replacement therapy and incidence of Alzheimer disease in older women: The Cache County Study. JAMA 2002; 288(19):2123-2129.

95. Shumaker SA, Legault C, Rapp SR, et al. Estrogen plus progestin and incidence of dementia and mild cognitive impairment in postmenopausal women: The Women’s Health Initiative Memory Study: A randomized controlled trial. JAMA. 2003;289(20): 2651-2662.

96. Haapasaari K-M, Raudaskoski T, Kallioinen M, et al. Systemic Therapy with estrogen or estrogen with progestin has no effect on skin collagen in postmenopausal women. Maturitas 1997;27: 153-162.

97. Chen L, Dyson M, Rymer J, et al. The use of high-frequency diagnostic ultrasound to investigate the effect of hormone replacement therapy on skin thickness. Skin Res Technol 2001;7: 95-97.